Table 2.
Univariate analysis of associations between various parameters and prostate-specific antigen progression-free survival in patients with castrate-resistant prostate cancer who received cabazitaxel.
| Variables (n, %) | Univariate analysis |
||
|---|---|---|---|
| HR 95% CI | p value | ||
| Age (years) | 0.83 | 0.5818 | |
| ≧75 | 24 (43.6) | (0.42-1.62) | |
| ˂75 | 31 (56.4) | ||
| PS | 1.24 | 0.6908 | |
| 2-3 | 6 (12.7) | (0.43-3.55) | |
| 0-1 | 49 (87.3) | ||
| PSA (ng/ml) | 2.32 | 0.0150* | |
| ≧35 | 27 (49.1) | (1.18-4.57) | |
| ˂35 | 28 (50.9) | ||
| Time to CRPC (months) | 1.05 | 0.8886 | |
| ≧12 | 28 (50.9) | (0.54-2.04) | |
| ˂12 | 27 (49.1) | ||
| Number of pretreatment drugs | 1.04 | 0.8484 | |
| ˃4 | 29 (52.3) | (0.51-1.84) | |
| ≦4 | 26 (47.7) | ||
| Number of new hormonal agents used | 0.97 | 0.9324 | |
| 2 | 20 (36.4) | (0.70-1.55) | |
| 1 | 20 (36.4) | ||
| 0 | 15 (27.2) | ||
| Cabazitaxel dose(mg/m2) | 0.85 | 0.6201 | |
| ˃20 | 33 (60.0) | (0.44-1.63) | |
| ≦20 | 22 (40.0) | ||
| Grade 3/4 neutropenia | 1.09 | 0.7995 | |
| Yes | 29 (52.3) | (0.57-2.07) | |
| No | 26 (47.7) | ||
| NLR (n = 48) | 1.55 | 0.2400 | |
| ˃3.6 | 24 (50.0) | (0.75-3.22) | |
| ≦3.6 | 24 (50.0) | ||
| Total Gleason score (n = 44) | 1.03 | 0.9437 | |
| ˃8 | 29 (65.9) | (0.50-2.09) | |
| ≦8 | 15 (34.1) | ||
| Visceral metastasis (n = 34) | 2.23 | 0.1171 | |
| Yes | 9(26.5) | (2.82-6.11) | |
| No | 17(73.5) | ||
*p < 0.05.
PS, performance status; CRPC, castrate-resistant prostate cancer; NLR, neutrophil/lymphocyte ratio; HR, hazard ratio; PSA, prostate-specific antigen.